Our Pipeline

Mycovia is committed to the development of a robust pipeline of novel therapies to address the needs of patients living with overlooked medical conditions in women’s health and beyond.

Disease Indication
Phase 1
Phase 2
Phase 3
NDA Submitted
Oteseconazole (VT-1161)
Invasive & opportunistic infections
Emerging MDR-fungi (Candida auris)
Cryptococcal meningitis (Cryptococcus neoformans)
Valley fever (Coccidioides)

Source: Mycovia Source Data on File

Worldwide clinical trials were completed for oteseconazole.

Find out more

Page Banner Image